Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$1.86 - $2.62 $411,528 - $579,680
-221,252 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$2.29 - $3.88 $27,869 - $47,219
12,170 Added 5.82%
221,252 $553,000
Q4 2021

Feb 14, 2022

SELL
$3.43 - $4.65 $349,719 - $474,109
-101,959 Reduced 32.78%
209,082 $779,000
Q3 2021

Nov 15, 2021

SELL
$3.1 - $4.32 $322,272 - $449,102
-103,959 Reduced 25.05%
311,041 $1.25 Million
Q3 2020

Nov 16, 2020

BUY
$3.91 - $7.15 $1.62 Million - $2.97 Million
415,000 New
415,000 $1.76 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.